<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JCP</journal-id>
<journal-id journal-id-type="hwp">jclinpharm</journal-id>
<journal-id journal-id-type="nlm-ta">J Clin Pharmacol</journal-id>
<journal-title>The Journal of Clinical Pharmacology</journal-title>
<issn pub-type="ppub">0091-2700</issn>
<issn pub-type="epub">1552-4604</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0091270010395939</article-id>
<article-id pub-id-type="publisher-id">10.1177_0091270010395939</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Brief Report</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Limited Sampling Strategies for the Estimation of Raltegravir Daily Exposure in HIV-Infected Patients</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Cattaneo</surname><given-names>Dario</given-names></name>
<degrees>PharmD, PhD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Ripamonti</surname><given-names>Diego</given-names></name>
<degrees>MD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Gervasoni</surname><given-names>Cristina</given-names></name>
<degrees>MD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Landonio</surname><given-names>Simona</given-names></name>
<degrees>MD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Meraviglia</surname><given-names>Paola</given-names></name>
<degrees>MD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Baldelli</surname><given-names>Sara</given-names></name>
<degrees>ChemD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Cozzi</surname><given-names>Valeria</given-names></name>
<degrees>BiolSciD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Fucile</surname><given-names>Serena</given-names></name>
<degrees>BiolSciD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Clementi</surname><given-names>Emilio</given-names></name>
<degrees>MD</degrees>
</contrib>
</contrib-group>
<aff id="aff1-0091270010395939">Unit of Clinical Pharmacology, Luigi Sacco University Hospital, Milan, Italy (Dr Cattaneo, Dr Baldelli, Dr Cozzi, Dr Fucile, Dr Clementi)</aff>
<aff id="aff2-0091270010395939">Antiviral Therapy Unit, Infectious Diseases Unit–Ospedali Riuniti di Bergamo, Italy (Dr Ripamonti)</aff>
<aff id="aff3-0091270010395939">I Division of Infectious Diseases Luigi Sacco Hospital (Dr Landonio)</aff>
<aff id="aff4-0091270010395939">II Division of Infectious Diseases Luigi Sacco Hospital (Dr Meraviglia,)</aff>
<aff id="aff5-0091270010395939">III Division of Infectious Diseases Luigi Sacco Hospital (Dr Gervasoni)</aff>
<aff id="aff6-0091270010395939">Università degli Studi di Milano, Milan, Italy (Dr Cattaneo, Dr Gervasoni, Dr Baldelli, Dr Cozzi, Dr Fucile, Dr Clementi)</aff>
<aff id="aff7-0091270010395939">E Medea Scientific Institute, Bosisio Parini, Italy (Dr Clementi)</aff>
<author-notes>
<corresp id="corresp1-0091270010395939">Dario Cattaneo, Unit of Clinical Pharmacology, Luigi Sacco University Hospital, via GB Grassi 74, 20157 Milano, Italy; e-mail: <email>cattaneo.dario@hsacco.it</email>.</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>3</month>
<year>2012</year>
</pub-date>
<volume>52</volume>
<issue>3</issue>
<fpage>440</fpage>
<lpage>445</lpage>
<history>
<date date-type="received">
<day>19</day>
<month>10</month>
<year>2010</year>
</date>
<date date-type="accepted">
<day>3</day>
<month>12</month>
<year>2010</year>
</date>
</history>
<permissions>
<copyright-statement>© 2012 American College of Clinical Pharmacology, Inc.</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">American College of Clinical Pharmacology, Inc.</copyright-holder>
</permissions>
<abstract>
<p>Stepwise multiple regression analyses were applied to 50 raltegravir pharmacokinetic profiles from 50 HIV patients with the goal to identify limited sampling strategies for the prediction of drug area under the time–concentration curve (AUC<sub>0-12</sub>). Raltegravir single sampling point-based equations failed to reliably predict daily drug exposure. Conversely, different algorithms based on few samples and associated with good correlation, acceptable bias, and imprecision with the measured raltegravir AUC<sub>0-12</sub> were identified. These models could used to predict raltegravir exposure for clinic or research purposes.</p>
</abstract>
<kwd-group>
<kwd>Pharmacokinetics</kwd>
<kwd>HIV</kwd>
<kwd>raltegravir</kwd>
<kwd>limited sampling strategies</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>Raltegravir (RAL) is the first approved HIV-1 integrase inhibitor targeting the strand transfer step of HIV-1 integration.<sup><xref ref-type="bibr" rid="bibr1-0091270010395939">1</xref>,<xref ref-type="bibr" rid="bibr2-0091270010395939">2</xref></sup> Clinical trials have demonstrated that RAL-containing regimens have potent antiretroviral activity and are well tolerated both in HIV antiretroviral treatment–experienced<sup><xref ref-type="bibr" rid="bibr3-0091270010395939">3</xref>,<xref ref-type="bibr" rid="bibr4-0091270010395939">4</xref></sup> and antiretroviral-naïve<sup><xref ref-type="bibr" rid="bibr5-0091270010395939">5</xref>,<xref ref-type="bibr" rid="bibr6-0091270010395939">6</xref></sup> individuals. High interindividual variability in the plasma concentrations of RAL has been observed both in healthy subjects and in HIV patients, also when the drug was given at fixed doses.<sup><xref ref-type="bibr" rid="bibr7-0091270010395939">7</xref>-<xref ref-type="bibr" rid="bibr9-0091270010395939">9</xref></sup> Although no clear pharmacokinetic–pharmacodynamic relationships are established for RAL, high variability in the daily drug exposure might represent a clinical concern given its potential to provide HIV patients with suboptimal dosage.</p>
<p>RAL trough plasma concentration is increasingly used as biomarker of daily patient exposure to the drug.<sup><xref ref-type="bibr" rid="bibr10-0091270010395939">10</xref>-<xref ref-type="bibr" rid="bibr12-0091270010395939">12</xref></sup> Nevertheless, the value of trough concentrations to predict daily exposure to RAL in a reliable way is still unproven. More accurate and informative may be the monitoring of the area under the time–concentration curve (AUC<sub>0-12</sub>), which, however, is cumbersome for both patients and clinical staff and expensive for routine use, since it requires multiple blood sampling throughout the 12-hour postdosing period. A suitable alternative approach would be the use of algorithms that allow the estimation of total AUC based on few blood samples.<sup><xref ref-type="bibr" rid="bibr13-0091270010395939">13</xref>-<xref ref-type="bibr" rid="bibr17-0091270010395939">17</xref></sup> These limited sampling strategies (LSS) have already been proposed for some antiretroviral agents including nevirapine, nelfinavir, and saquinavir,<sup><xref ref-type="bibr" rid="bibr13-0091270010395939">13</xref>-<xref ref-type="bibr" rid="bibr15-0091270010395939">15</xref></sup> whereas no data are available for RAL.</p>
<p>The present study was designed to (1) evaluate RAL pharmacokinetics in HIV-infected patients treated with the same drug doses for at least 1 month (steady-state conditions); (2) test the value of RAL trough concentrations to predict RAL AUC<sub>0-12</sub>; and (3) identify equations that enable accurate and precise evaluation of the RAL AUC<sub>0-12</sub> on the basis of the least number of blood sampling collected within the first hours after drug dosing.</p>
<sec id="section1-0091270010395939" sec-type="methods">
<title>Methods</title>
<sec id="section2-0091270010395939">
<title>Study Population</title>
<p>Fifty HIV-infected patients followed at Antiviral Unit of the Ospedali Riuniti Bergamo (Italy) or at the Department of Infectious Disease of the Luigi Sacco University Hospital (Milan, Italy) were included in the study. Maintenance highly active antiretroviral therapy (HAART) was with RAL 400 mg twice daily in association with atazanavir (n = 43) or etravirine (n = 7). Only patients given the combination drugs for at least 1 month were included in the pharmacokinetic evaluations in order to ensure steady-state conditions. The study was approved by the local ethics committees, and all patients gave written informed consent before participation in the study.</p>
</sec>
<sec id="section3-0091270010395939">
<title>Study Design and Pharmacokinetic Measurements</title>
<p>On the morning of the pharmacokinetic studies, blood samples were collected for the measurement of RAL plasma trough concentrations. Then patients were given the morning HAART doses in the presence of the nursing staff. RAL pharmacokinetic analysis was based on EDTA-collected blood samples from antecubital vein drawn at 0, 1, 2, 3, 4, 8, and 12 hours after the morning dose. We considered as acceptable a deviation from the scheduled sampling time of ±5 minutes. Plasma was separated from blood cell fractions within 1 hour from drawing, and samples were stored at −70°C until analysis. The AUC from time zero to the last sampling point was calculated by trapezoidal rule.</p>
</sec>
<sec id="section4-0091270010395939">
<title>Pharmacokinetics Evaluations</title>
<p>RAL concentrations in plasma samples were determined by a high-performance liquid chromatography (HPLC) method coupled with tandem mass spectroscopy (LC-MS/MS) based on the assay originally developed by Fayet et al.<sup><xref ref-type="bibr" rid="bibr18-0091270010395939">18</xref></sup> The method was validated in agreement with the Consensus Guidelines on Bioanalytical Method Validations.<sup><xref ref-type="bibr" rid="bibr19-0091270010395939">19</xref></sup> Briefly, 100 µL of plasma samples containing the internal standard (quinoxaline) were extracted by protein precipitation procedure with acetonitrile. After centrifugation, an aliquot of the supernatant was analyzed by the LC-MS/MS system consisting of a Waters Alliance 2695 coupled with a Quattro Premier XE triple quadrupole (Waters, Italy). Chromatographic separation was performed under gradient conditions on a reversed-phase C18 column (Xbridge, 2.1 × 100 mm, 3.5-µm particle sizes, Waters, Milan, Italy) maintained at 50°C. The mass spectrometry was done in positive electron spray ionization mode.</p>
<p>For quantization, multiple-reaction monitoring (MRM) mode was applied to monitor the transitions from the precursor ions [M+H] + (m/z 445.05 for RGV and m/z 313.2 for quinoxaline) to the product ions (m/z 108.95 for RGV and m/z 246.3 for quinoxaline).The method was linear over the RAL concentration ranges of 10 to 5000 ng/mL. Between- and within-day imprecision and inaccuracy were less than 15%.</p>
</sec>
<sec id="section5-0091270010395939">
<title>Statistical Analysis</title>
<p>Normal distribution of the continuous variables was confirmed by the Kolmogorov-Smirnov test (eventually retested after logarithmic transformation). Nonnormally distributed variables were expressed as median (interquartile range) and normally distributed variables as mean ± standard deviation. Between-patient variability in the RAL pharmacokinetic parameters was expressed as the coefficient of variation (CV%).</p>
<p>The relative power of single or combination plasma RAL concentration–time points to predict the drug AUC<sub>0-12</sub> estimated from the whole pharmacokinetic profile was assessed by multiple stepwise regression analysis.<sup><xref ref-type="bibr" rid="bibr16-0091270010395939">16</xref>,<xref ref-type="bibr" rid="bibr17-0091270010395939">17</xref></sup> Pharmacokinetic data were randomly split into 2 groups, development (n = 25) and validation (n = 25) sets. Single and multiple linear regression models using 1 to 5 concentration–time points as independent variables were developed. Because blood sampling late after drug dosing would be impractical in outpatient clinics, the multiple linear regression analysis was limited to samples collected within 4 hours after RAL administration. Predictive equations extrapolated from the LSS development set were then tested in the LSS validation set. Agreement between measured and predicted RAL AUC was defined by linear correlation between the 2 series (measured vs predicted AUC) and by the assessment of bias and imprecision, according to current guidelines.<sup><xref ref-type="bibr" rid="bibr16-0091270010395939">16</xref>,<xref ref-type="bibr" rid="bibr20-0091270010395939">20</xref></sup> The bias was measured by the mean prediction error (ME), whereas the imprecision was represented by the root mean squared prediction error (RMSE) and by mean absolute error (MAE). All statistical analyses were performed using MedCalc (MedCalc Software Mariakerke, Belgium).</p>
</sec>
</sec>
<sec id="section6-0091270010395939" sec-type="results">
<title>Results</title>
<sec id="section7-0091270010395939">
<title>RAL Pharmacokinetic Studies</title>
<p>Fifty RAL pharmacokinetic profiles were collected from 50 HIV-infected patients. At the time of the pharmacokinetic evaluation, all patients had normal renal function (mean serum creatinine 0.9 ± 0.1 mg/dL) and no clinical signs of liver insufficiency (serum transaminases &lt;100 IU/L). No major differences were observed in the demographic and hematochemical characteristics between the development and validation sets (<xref ref-type="table" rid="table1-0091270010395939">Table I</xref>).</p>
<table-wrap id="table1-0091270010395939" position="float">
<label>Table I</label>
<caption><p>Patients’ Baseline Demographic and Hematochemical Characteristics</p></caption>
<graphic alternate-form-of="table1-0091270010395939" xlink:href="10.1177_0091270010395939-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Variables</th>
<th align="center">Development Set (n = 25)</th>
<th align="center">Validation Set (n = 25)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y</td>
<td>44 ± 8</td>
<td>46 ± 9</td>
</tr>
<tr>
<td>Male, n</td>
<td>18</td>
<td>16</td>
</tr>
<tr>
<td>Body mass index, kg/m<sup>2</sup></td>
<td>24 ± 8</td>
<td>26 ± 7</td>
</tr>
<tr>
<td>CD4 count, cells/µL</td>
<td>580 (420-684)</td>
<td>537 (415-650)</td>
</tr>
<tr>
<td>Cholesterol, mg/dL</td>
<td>199 ± 43</td>
<td>208 ± 48</td>
</tr>
<tr>
<td>Triglycerides, mg/dL</td>
<td>128 ± 58</td>
<td>228 ± 323</td>
</tr>
<tr>
<td>HDL, mg/dL</td>
<td>51 ± 17</td>
<td>52 ± 16</td>
</tr>
<tr>
<td>Serum creatinine, mg/dL</td>
<td>0.9 ± 0.1</td>
<td>0.9 ± 0.1</td>
</tr>
<tr>
<td>AST, IU/L</td>
<td>28 ± 9</td>
<td>30 ± 9</td>
</tr>
<tr>
<td>ALT, IU/L</td>
<td>34 ± 16</td>
<td>38 ± 27</td>
</tr>
<tr>
<td>GGT, IU/L</td>
<td>44 ± 50</td>
<td>82 ± 98</td>
</tr>
<tr>
<td colspan="3">Concomitant HAART, n</td>
</tr>
<tr>
<td> Atazanavir</td>
<td>22</td>
<td>21</td>
</tr>
<tr>
<td> Etravirine</td>
<td>3</td>
<td>4</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0091270010395939">
<p>ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, γ-glutamyl transferase; HAART, highly active antiretroviral therapy; HDL, high-density lipoprotein.</p>
</fn>
<fn id="table-fn2-0091270010395939">
<p>Data given as mean ± standard deviation or as median (interquartile ratio), as deemed appropriate.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>The main RAL pharmacokinetic parameters are summarized in <xref ref-type="table" rid="table2-0091270010395939">Table II</xref>. Large interindividual distribution of RAL AUC<sub>0-12</sub> was observed (<xref ref-type="fig" rid="fig1-0091270010395939">Figure 1</xref>). Similarly, RAL trough concentration was the parameter with the highest interpatient variability, having a CV% greater than 100%. Of note, the time to maximum concentration of RAL ranged from 0 to 8 hours post dosing (<xref ref-type="table" rid="table2-0091270010395939">Table II</xref>). Wide distribution in the main RAL pharmacokinetic parameters was observed also when data were randomly split into the development and validation sets (<xref ref-type="table" rid="table2-0091270010395939">Table II</xref>). The scatter plot of the individual plasma concentrations vs time in the development and in the validation sets evidenced comparable distribution of the daily RAL concentrations (<xref ref-type="fig" rid="fig2-0091270010395939">Figure 2</xref>), which was markedly variable in the first 3 hours after drug administration.</p>
<table-wrap id="table2-0091270010395939" position="float">
<label>Table II</label>
<caption><p>Summary of the Main Raltegravir (RAL) Pharmacokinetic Parameters</p></caption>
<graphic alternate-form-of="table2-0091270010395939" xlink:href="10.1177_0091270010395939-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Parameters</th>
<th align="center">Mean ± SD or Median (IQR)</th>
<th align="center">Range</th>
<th align="center">CV%<sup><xref ref-type="table-fn" rid="table-fn4-0091270010395939">a</xref></sup></th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="4">Overall (n = 50)</td>
</tr>
<tr>
<td> C<sub>0</sub>, ng/mL</td>
<td>524 ± 534</td>
<td>15-2223</td>
<td>102</td>
</tr>
<tr>
<td> C<sub>max</sub>, ng/mL</td>
<td>3050 ± 2049</td>
<td>116-10 773</td>
<td>67</td>
</tr>
<tr>
<td> t<sub>max</sub>, h</td>
<td>1 (1-2)</td>
<td>0-8</td>
<td>94</td>
</tr>
<tr>
<td> t<sub>1/2</sub>, h</td>
<td>2.51 ± 1.59</td>
<td>0.83-9.03</td>
<td>63</td>
</tr>
<tr>
<td> AUC<sub>0-12</sub>, ng·h/mL</td>
<td>10 595 ± 7289</td>
<td>728-35 652</td>
<td>69</td>
</tr>
<tr>
<td colspan="4">Development set (n = 25)</td>
</tr>
<tr>
<td> C<sub>0</sub>, ng/mL</td>
<td>509 ± 586</td>
<td>16-2223</td>
<td/>
</tr>
<tr>
<td> C<sub>max</sub>, ng/mL</td>
<td>2730 ± 2974</td>
<td>116-9461</td>
<td/>
</tr>
<tr>
<td> AUC<sub>0-12</sub>, ng·h/mL</td>
<td>9272 ± 9276</td>
<td>728-25 674</td>
<td/></tr>
<tr>
<td colspan="4">Validation set (n = 25)</td>
</tr>
<tr>
<td> C<sub>0</sub>, ng/mL</td>
<td>519 ± 490</td>
<td>15-1901</td>
<td/>
</tr>
<tr>
<td> C<sub>max</sub>, ng/mL</td>
<td>3344 ± 2038</td>
<td>561-10 773</td>
<td/>
</tr>
<tr>
<td> AUC<sub>0-12</sub>, ng·h/mL</td>
<td>11 867 ± 5817</td>
<td>2625-35 652</td>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-0091270010395939">
<p>AUC<sub>0-12</sub>, area under the time–concentration curve; C<sub>0</sub>, trough concentration; C<sub>max</sub>, maximum concentration; CV%, coefficient of variation; IQR, interquartile range; SD, standard deviation; tmax, time to C<sub>max</sub>; t1/2, half-life.</p>
</fn>
<fn id="table-fn4-0091270010395939">
<label>a</label>
<p>Interpatient variability.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<fig id="fig1-0091270010395939" position="float">
<label>Figure 1.</label>
<caption><p>Box plot of raltegravir (RAL) area under the time– concentration curve (AUC<sub>0-12</sub>) measured in 50 HIV-infected patients given RAL as part of their highly active antiretroviral therapy (HAART) regimen.</p></caption>
<graphic xlink:href="10.1177_0091270010395939-fig1.tif"/>
</fig>
<fig id="fig2-0091270010395939" position="float">
<label>Figure 2.</label>
<caption><p>Scatter plot of individual plasma concentrations vs time measured in the development set (upper panel) and in the validation set (lower panel). RAL, raltegravir.</p></caption>
<graphic xlink:href="10.1177_0091270010395939-fig2.tif"/>
</fig>
</sec>
<sec id="section8-0091270010395939">
<title>Prediction of RAL Daily Exposure by Single- and Multiple-Point Equations</title>
<p>As shown in <xref ref-type="table" rid="table3-0091270010395939">Table III</xref>, the correlation between RAL trough (C<sub>0</sub>) concentration and the corresponding AUC<sub>0-12</sub> was poor (model 7, coefficient of correlation, <italic>r</italic> = 0.359), whereas the best association was found with concentrations measured at 4 hours after drug administration (model 11, <italic>r</italic> = 0.811). However, the predictive performance of single point-based equations (models 7-11, <xref ref-type="table" rid="table3-0091270010395939">Table III</xref>) was unacceptable, with bias and imprecision always out of the common acceptable range of ±20%.<sup><xref ref-type="bibr" rid="bibr16-0091270010395939">16</xref></sup></p>
<table-wrap id="table3-0091270010395939" position="float">
<label>Table III</label>
<caption><p>Limited Sampling Strategies for the Prediction of Raltegravir (RAL) AUC<sub>0-12</sub></p></caption>
<graphic alternate-form-of="table3-0091270010395939" xlink:href="10.1177_0091270010395939-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Model</th>
<th align="center">Equation</th>
<th align="center">Correlation (<italic>r</italic>)</th>
<th align="center">ME, %</th>
<th align="center">RMSE, %</th>
<th align="center">MAE, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>AUC<sub>0-12</sub> = 2.082C<sub>0</sub> + 0.821C<sub>1</sub> + 1.238C<sub>2</sub> − 0.210C<sub>3</sub> + 4.280C<sub>4</sub> + 783.1</td>
<td>0.978</td>
<td>−0.6</td>
<td>10.0</td>
<td>6.7</td>
</tr>
<tr>
<td>2</td>
<td>AUC<sub>0-12</sub> = 2.089C<sub>0</sub> + 0.819C<sub>1</sub> + 1.193C<sub>2</sub> + 4.051C<sub>4</sub> + 780.3</td>
<td>0.958</td>
<td>−0.5</td>
<td>10.1</td>
<td>6.8</td>
</tr>
<tr>
<td>3</td>
<td>AUC<sub>0-12</sub> = 2.145C<sub>0</sub> + 0.791C<sub>1</sub> + 0.510C<sub>2</sub> + 3.410C<sub>3</sub> + 1060.1</td>
<td>0.925</td>
<td>−0.1</td>
<td>19.2</td>
<td>13.7</td>
</tr>
<tr>
<td>4</td>
<td>AUC<sub>0-12</sub> = 2.289C<sub>0</sub> + 1.5153C<sub>2</sub> + 4.026C<sub>4</sub> + 1588.1</td>
<td>0.957</td>
<td>−2.8</td>
<td>14.5</td>
<td>11.1</td>
</tr>
<tr>
<td>5</td>
<td>AUC<sub>0-12</sub> = 0.876C<sub>1</sub> + 1.201C<sub>2</sub> + 3.994C<sub>4</sub> + 1824.2</td>
<td>0.951</td>
<td>−0.2</td>
<td>14.9</td>
<td>9.9</td>
</tr>
<tr>
<td>6</td>
<td>AUC<sub>0-12</sub> = 1.3604AUC<sub>0-4</sub> + 1655.4</td>
<td>0.888</td>
<td>−0.1</td>
<td>22.8</td>
<td>16.8</td>
</tr>
<tr>
<td>7</td>
<td>AUC<sub>0-12</sub> = 1.386C<sub>0</sub> + 9882.6</td>
<td>0.359</td>
<td>−10.7</td>
<td>47.6</td>
<td>38.4</td>
</tr>
<tr>
<td>8</td>
<td>AUC<sub>0-12</sub> = 1.933C<sub>1</sub> + 6837.1</td>
<td>0.589</td>
<td>−4.7</td>
<td>39.3</td>
<td>30.9</td>
</tr>
<tr>
<td>9</td>
<td>AUC<sub>0-12</sub> = 2.304C<sub>2</sub> + 5915.8</td>
<td>0.642</td>
<td>−4.2</td>
<td>37.2</td>
<td>29.5</td>
</tr>
<tr>
<td>10</td>
<td>AUC<sub>0-12</sub> = 3.728C<sub>3</sub> + 4054.5</td>
<td>0.795</td>
<td>−4.4</td>
<td>29.9</td>
<td>22.6</td>
</tr>
<tr>
<td>11</td>
<td>AUC<sub>0-12</sub> = 4.638C<sub>4</sub> + 5236.3</td>
<td>0.811</td>
<td>−4.9</td>
<td>28.9</td>
<td>24.0</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn5-0091270010395939">
<p>AUC<sub>0-12</sub>, area under the time–concentration curve; MAE, mean absolute error; ME, mean prediction error; RMSE, root mean squared prediction error.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>By stepwise regression analyses, different equations based on multiple sampling points collected within the first 4 hours after RAL administration were identified. As shown in <xref ref-type="table" rid="table3-0091270010395939">Table III</xref>, most of these algorithms showed high correlation with the measured RAL AUC<sub>0-12</sub>. The best model was that including all plasma RAL concentrations measured in the first 4 hours after drug intake (model 1, <xref ref-type="table" rid="table3-0091270010395939">Table III</xref>). Indeed, this algorithm was associated with the highest correlation coefficient (<italic>r</italic> = 0.978), the lowest mean percentage error (1.2% ± 10.9%), and optimal bias and imprecision (ME, MAE, and MRSE within 10%). Nevertheless, other models based on fewer sampling points and associated with acceptable performance were also identified (models 2-5, <xref ref-type="table" rid="table3-0091270010395939">Table III</xref>).</p>
</sec>
</sec>
<sec id="section9-0091270010395939" sec-type="discussion">
<title>Discussion</title>
<p>The present study documents that in HIV-infected patients treated with the same drug dose (400 mg twice daily), the daily RAL pharmacokinetic profiles are highly variable, as shown by wide range distribution of RAL AUC<sub>0-12</sub> measures and individual daily plasma concentrations. The highest variability was found for RAL concentrations measured in the first 3 hours after the morning dose administration. In particular, the RAL trough level showed nearly a 150-fold variability in the measured concentrations and was associated with an interpatient CV% greater than 100%. These results are in line with previous findings<sup><xref ref-type="bibr" rid="bibr7-0091270010395939">7</xref>-<xref ref-type="bibr" rid="bibr9-0091270010395939">9</xref></sup> and underline the potential importance of implementing individual RAL therapeutic schemes guided by routine monitoring of drug plasma concentrations.</p>
<p>For drugs with high variability in daily exposure, like RAL, measurement of AUC from the complete pharmacokinetic profile is the best tool to guide drug dosing but is hardly applicable in day-to-day outpatient follow-up. This pharmacokinetic parameter can be predicted, however, by limited sampling strategies aimed at minimizing the number of blood samples needed.<sup><xref ref-type="bibr" rid="bibr16-0091270010395939">16</xref></sup> Algorithms to define limited blood sampling strategies to ensure reliable AUC predictions have been proposed previously for monitoring of nevirapine, nelfinavir, and saquinavir.<sup><xref ref-type="bibr" rid="bibr13-0091270010395939">13</xref>-<xref ref-type="bibr" rid="bibr15-0091270010395939">15</xref></sup> No similar studies were available for RAL. Here we developed for the first time LSS based on multiple regression analysis to predict RAL exposure using daily pharmacokinetic profiles from HIV patients given the drug in combination with atazanavir or with etravirine. Considering single sample-point equations, C<sub>3</sub> and C<sub>4</sub> concentrations were those that best correlated with the measured RAL AUC<sub>0-12</sub>. However, these equations were associated with unacceptable bias and imprecision. Similarly, RAL trough concentrations largely failed to reliably predict daily exposure of patients to the drug. These findings clearly indicate that the measure of RAL trough concentrations cannot be used for therapeutic drug monitoring in routine clinical practice. For the same reasons, C<sub>0</sub>-based approaches cannot be applied to monitor RAL exposure in clinical trials. Therefore, it can not be excluded that findings from recent studies aimed at investigating potential drug-to-drug interactions between RAL and other HAART in HIV-infected individuals might have been biased by the use of RAL trough concentration as the only pharmacokinetic biomarker of daily drug exposure.<sup><xref ref-type="bibr" rid="bibr10-0091270010395939">10</xref>-<xref ref-type="bibr" rid="bibr12-0091270010395939">12</xref></sup></p>
<p>By performing regression analyses and using near-peak multiple plasma RAL concentrations, we have identified different LSS that provide better performance than the single-point strategies in predicting RAL AUC<sub>0-12</sub>. Besides higher correlation coefficients, the multiple sampling models were indeed associated with a very low distribution of the mean error, as well as optimal bias (as ME) and imprecision (as RMSE, MAE), with measures within the accepted range of ±20%.<sup><xref ref-type="bibr" rid="bibr16-0091270010395939">16</xref>,<xref ref-type="bibr" rid="bibr17-0091270010395939">17</xref></sup> Therefore, most of these algorithms—based on a few blood sampling points to be collected very shortly after RAL administration (such as models 4 and 5, which require the collection of only 3 samples)—are ideal candidates to predict daily drug exposure not only for research purpose but also in routine clinical practice.</p>
<p>The proposed LSS for the prediction of daily RAL AUC may present limitations. Because multiple regression analyses depend on timed concentrations for prediction of AUC, sampling time is critical. Deviation from the target sampling times may significantly affect the accuracy of AUC prediction. This limitation could be overcome by nonlinear mixed effects modeling methods, which have flexibility in the sampling time and the possibility of continuously updating the model by incorporating novel data into the population parameters, thus refining prediction and improving performance.<sup><xref ref-type="bibr" rid="bibr17-0091270010395939">17</xref></sup> These Bayesian-derived LSS, however, require specialized software programs and extensive operator training, which are not available in most laboratories from public hospitals.</p>
<p>In conclusion, this work presents new limited sampling strategies for the reliable and feasible estimation of RAL AUC<sub>0-12</sub> in HIV-infected individuals. Whether the application of these algorithms will optimize RAL therapy and improve clinical outcome in HIV patients remains to be established.</p>
</sec>
</body>
<back>
<ack><p>We thank the Fondazione Romeo ed Enrica Invernizzi for continuous support for the research.</p></ack>
<fn-group>
<fn fn-type="financial-disclosure">
<p>Financial disclosure: none declared.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0091270010395939">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Steigbigel</surname><given-names>RT</given-names></name>
<name><surname>Cooper</surname><given-names>DA</given-names></name>
<name><surname>Kumar</surname><given-names>PN</given-names></name>
<etal/>
</person-group>. <article-title>Raltegravir with optimized background therapy for resistant HIV-1 infection</article-title>. <source>N Engl J Med</source>. <year>2008</year>;<volume>359</volume>:<fpage>339</fpage>-<lpage>354</lpage>.</citation>
</ref>
<ref id="bibr2-0091270010395939">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Eron</surname><given-names>JJ</given-names><suffix>Jr</suffix></name>
</person-group>. <article-title>Antiretroviral therapy: new drugs, formulations, ideas, and strategies</article-title>. <source>Top HIV Med</source>. <year>2009</year>;<volume>17</volume>:<fpage>146</fpage>-<lpage>150</lpage>.</citation>
</ref>
<ref id="bibr3-0091270010395939">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gupta</surname><given-names>S</given-names></name>
<name><surname>Lataillade</surname><given-names>M</given-names></name>
<name><surname>Farber</surname><given-names>S</given-names></name>
<name><surname>Kozal</surname><given-names>MJ</given-names></name>
</person-group>. <article-title>Raltegravir with unboosted atazanavir 300 mg twice daily in antiretroviral treatment-experienced participants</article-title>. <source>J Int Assoc Physicians AIDS Care</source>. <year>2009</year>;<volume>8</volume>:<fpage>87</fpage>-<lpage>92</lpage>.</citation>
</ref>
<ref id="bibr4-0091270010395939">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ward</surname><given-names>D</given-names></name>
</person-group>. <article-title>Efficacy and safety of an NRTI-sparing dual regimen of raltegravir and ritonavir-boosted protease inhibitor in a triple antiretroviral class-experienced population</article-title>. <source>HIV Clin Trials</source>. <year>2009</year>;<volume>10</volume>:<fpage>337</fpage>-<lpage>340</lpage>.</citation>
</ref>
<ref id="bibr5-0091270010395939">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Croxtall</surname><given-names>JD</given-names></name>
<name><surname>Scott</surname><given-names>LJ</given-names></name>
</person-group>. <article-title>Raltegravir: in treatment-naive patients with HIV-1 infection</article-title>. <source>Drugs</source>. <year>2010</year>;<volume>70</volume>:<fpage>631</fpage>-<lpage>642</lpage>.</citation>
</ref>
<ref id="bibr6-0091270010395939">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Markowitz</surname><given-names>M</given-names></name>
<name><surname>Nguyen</surname><given-names>BY</given-names></name>
<name><surname>Gotuzzo</surname><given-names>E</given-names></name>
<etal/>
</person-group>. <article-title>Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study</article-title>. <source>J Acquir Immune Defic Syndr</source>. <year>2007</year>;<volume>46</volume>:<fpage>125</fpage>-<lpage>133</lpage>.</citation>
</ref>
<ref id="bibr7-0091270010395939">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ter Heine</surname><given-names>R</given-names></name>
<name><surname>Mulder</surname><given-names>JW</given-names></name>
<name><surname>van Gorp</surname><given-names>EC</given-names></name>
<name><surname>Wagenaar</surname><given-names>JF</given-names></name>
<name><surname>Beijnen</surname><given-names>JH</given-names></name>
<name><surname>Huitema</surname><given-names>AD</given-names></name>
</person-group>. <article-title>Intracellular and plasma steady-state pharmacokinetics of raltegravir, darunavir, etravirine and ritonavir in heavily pre-treated HIV-infected patients</article-title>. <source>Br J Clin Pharmacol</source>. <year>2010</year>;<volume>69</volume>: <fpage>475</fpage>-<lpage>483</lpage>.</citation>
</ref>
<ref id="bibr8-0091270010395939">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Iwamoto</surname><given-names>M</given-names></name>
<name><surname>Wenning</surname><given-names>LA</given-names></name>
<name><surname>Petry</surname><given-names>AS</given-names></name>
<etal/>
</person-group>. <article-title>Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects</article-title>. <source>Clin Pharmacol Ther</source>. <year>2008</year>;<volume>83</volume>:<fpage>293</fpage>-<lpage>299</lpage>.</citation>
</ref>
<ref id="bibr9-0091270010395939">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cattaneo</surname><given-names>D</given-names></name>
<name><surname>Ripamonti</surname><given-names>D</given-names></name>
<name><surname>Baldelli</surname><given-names>S</given-names></name>
<name><surname>Cozzi</surname><given-names>V</given-names></name>
<name><surname>Conti</surname><given-names>F</given-names></name>
<name><surname>Clementi</surname><given-names>E</given-names></name>
</person-group>. <article-title>Exposure-related effects of atazanavir on the pharmacokinetics of raltegravir in HIV-1-infected patients</article-title>. <source>Ther Drug Monit</source>. <year>2010</year>; <volume>32</volume>:<fpage>782</fpage>-<lpage>786</lpage>.</citation>
</ref>
<ref id="bibr10-0091270010395939">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Baroncelli</surname><given-names>S</given-names></name>
<name><surname>Villani</surname><given-names>P</given-names></name>
<name><surname>Weimer</surname><given-names>LE</given-names></name>
<etal/>
</person-group>. <article-title>Raltegravir plasma concentrations in treatment-experienced patients receiving salvage regimens based on raltegravir with and without maraviroc coadministration</article-title>. <source>Ann Pharmacother</source>. <year>2010</year>;<volume>44</volume>:<fpage>838</fpage>-<lpage>843</lpage>.</citation>
</ref>
<ref id="bibr11-0091270010395939">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tricot</surname><given-names>L</given-names></name>
<name><surname>Teicher</surname><given-names>E</given-names></name>
<name><surname>Peytavin</surname><given-names>G</given-names></name>
<etal/>
</person-group>. <article-title>Safety and efficacy of raltegravir in HIV-infected transplant patients cotreated with immunosuppressive drugs</article-title>. <source>Am J Transplant</source>. <year>2009</year>;<volume>9</volume>:<fpage>1946</fpage>-<lpage>1952</lpage>.</citation>
</ref>
<ref id="bibr12-0091270010395939">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ménard</surname><given-names>A</given-names></name>
<name><surname>Solas</surname><given-names>C</given-names></name>
<name><surname>Mokthari</surname><given-names>S</given-names></name>
<etal/>
</person-group>. <article-title>Etravirine-raltegravir, a marked interaction in HIV-1-infected patients: about four cases</article-title>. <source>AIDS</source>. <year>2009</year>;<volume>23</volume>:<fpage>869</fpage>-<lpage>871</lpage>.</citation>
</ref>
<ref id="bibr13-0091270010395939">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Veldkamp</surname><given-names>AI</given-names></name>
<name><surname>van Heeswijk</surname><given-names>RP</given-names></name>
<name><surname>Mulder</surname><given-names>JW</given-names></name>
<etal/>
</person-group>. <article-title>Limited sampling strategies for the estimation of the systemic exposure to the HIV-1 nonnucleoside reverse transcriptase inhibitor nevirapine</article-title>. <source>Ther Drug Monit</source>. <year>2001</year>;<volume>23</volume>:<fpage>606</fpage>-<lpage>611</lpage>.</citation>
</ref>
<ref id="bibr14-0091270010395939">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Regazzi</surname><given-names>MB</given-names></name>
<name><surname>Tinelli</surname><given-names>C</given-names></name>
<name><surname>Villani</surname><given-names>P</given-names></name>
<etal/>
</person-group>. <article-title>Limited sampling strategy for the estimation of systemic exposure to the protease inhibitor nelfinavir</article-title>. <source>Ther Drug Monit</source>. <year>2005</year>;<volume>27</volume>:<fpage>571</fpage>-<lpage>575</lpage>.</citation>
</ref>
<ref id="bibr15-0091270010395939">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dickinson</surname><given-names>L</given-names></name>
<name><surname>Back</surname><given-names>D</given-names></name>
<name><surname>Pozniak</surname><given-names>A</given-names></name>
<name><surname>Khoo</surname><given-names>S</given-names></name>
<name><surname>Boffito</surname><given-names>M</given-names></name>
</person-group>. <article-title>Limited-sampling strategy for the prediction of boosted hard-gel saquinavir exposure at a dosage of 1000/100 mg twice daily in human immunodeficiency virus-infected individuals</article-title>. <source>Ther Drug Monit</source>. <year>2007</year>;<volume>29</volume>:<fpage>361</fpage>-<lpage>367</lpage>.</citation>
</ref>
<ref id="bibr16-0091270010395939">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ting</surname><given-names>LS</given-names></name>
<name><surname>Villeneuve</surname><given-names>E</given-names></name>
<name><surname>Ensom</surname><given-names>MH</given-names></name>
</person-group>. <article-title>Beyond cyclosporine: a systematic review of limited sampling strategies for other immunosuppressants</article-title>. <source>Ther Drug Monit</source>. <year>2006</year>;<volume>28</volume>:<fpage>419</fpage>-<lpage>430</lpage>.</citation>
</ref>
<ref id="bibr17-0091270010395939">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>David</surname><given-names>O</given-names></name>
<name><surname>Johnston</surname><given-names>A</given-names></name>
</person-group>. <article-title>Limited sampling strategies</article-title>. <source>Clin Pharmacokinet</source>. <year>2000</year>;<volume>39</volume>:<fpage>311</fpage>-<lpage>313</lpage>.</citation>
</ref>
<ref id="bibr18-0091270010395939">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fayet</surname><given-names>A</given-names></name>
<name><surname>Béguin</surname><given-names>A</given-names></name>
<name><surname>Zanolari</surname><given-names>B</given-names></name>
<etal/></person-group>. <article-title>A LC-tandem MS assay for the simultaneous measurement of new antiretroviral agents: raltegravir, maraviroc, darunavir, and etravirine</article-title>. <source>J Chromatogr B Analyt Technol Biomed Life Sci</source>. <year>2007</year>;<volume>877</volume>:<fpage>1057</fpage>-<lpage>1069</lpage>.</citation>
</ref>
<ref id="bibr19-0091270010395939">
<label>19.</label>
<citation citation-type="book">
<collab><italic>FDA Guidance for Industry</italic></collab>. <source>Bioanalytical Method Validation</source>. <publisher-loc>Washington, DC</publisher-loc>: <publisher-name>Center for Drug Evaluation and Research, US Department for Health and Human Services</publisher-name>; <month>May</month> <year>2001</year>.</citation>
</ref>
<ref id="bibr20-0091270010395939">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sheiner</surname><given-names>LB</given-names></name>
<name><surname>Beal</surname><given-names>SL</given-names></name>
</person-group>. <article-title>Some suggestions for measuring predictive performance</article-title>. <source>J Pharmacokinet Biopharm</source>. <year>1981</year>;<volume>9</volume>:<fpage>503</fpage>-<lpage>512</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>